The HemOnc Pulse

Aditi Shastri, MD: Clinicians Need to ‘Come Together’ on TP53-Mutated MDS

Jan 18, 2024
Guest
Aditi Shastri, MD
Dr. Aditi Shastri, Assistant Professor of Medicine at Montefiore Einstein Comprehensive Cancer Center, discusses TP53-mutated MDS, treatment options, risk stratification tools, emerging drugs like IMETEL stat and sabatolimab, and the decision-making process of observing versus intervening in patients with MDS.
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 3min
2
Understanding TP53 Mutations in Myelodysplastic Syndrome
02:38 • 11min
3
Subclassifying Patients with Low-Risk and High-Risk MDS
14:00 • 2min
4
Upcoming Drugs and Research in MDS
15:53 • 2min
5
Observation vs Intervention in Patients with MDS
18:01 • 5min